Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitediadexus.com
CategoryBioTech
Phone650-246-6400
Employees
Founded1997
DescriptionMedical Diagnostic Developer

Offices

HQ
343 Oyster Point Boulevard
South San Francisco, CA, 94080-1913
USA

People

Chairman of the Board
Chief Financial Officer
CTO
President and Chief Executive Officer
Vice President of Medical Affairs
Board of Directors & Chairman Audit Committee
Board of Directors
Board of Directors
Show All People

Funding

Tags

diaDexus

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

The company’s lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

Recent Milestones

Videos

Screenshots

diaDexus screenshot
Above: diaDexus Screenshot -- #1
Uploaded: 6/20/09

Products

PLAC Test for Lp-PLA2

Websiteplactest.com

The PLAC Test for Lp-PLA2

The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis.

Early detection and more aggressive treatment can help prevent these cardiovascular events.

The PLAC Test measures Lp-PLA2 (lipoprotein-associated phospholipase A2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiac events. 50% of cardiovascular events strike in patients with unremarkable lipid levels, highlighting the prevalence of hidden cardiovascular risk. A substantial body of evidence including over 50 studies and abstracts in peer-reviewed journals and conferences support Lp-PLA2 as a cardiovascular risk marker that provides new information, over and above traditional risk factors. Consistent with ATP III guidelines, the PLAC Test should be used as an adjunct to traditional risk factor assessment to identify which moderate or high risk patients, as initially assessed by traditional risk factors, may actually be at higher risk. A decision algorithm has been developed to help you see how incorporating the PLAC Test into your clinical practice may help save lives. An elevated PLAC Test may indicate a need for more aggressive therapy, including treatment to lower LDL-C goals. Lipid lowering therapies, including statins, are proven to reduce cardiovascular events regardless of baseline LDL-C levels The PLAC Test is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. Since LDL has proven not to be a reliable predictor of stroke, the PLAC Test addresses this unmet clinical need. As of 2007, the PLAC Test is covered by Medicare at $47.43 and by a growing number of private payers. Currently, over 100 million Americans are covered for the PLAC Test. However, patients may be required to pay out-of-pocket — a small investment in their future health. The PLAC Test is available from clinical reference labs, hospitals and physician offices. For more information on the PLAC Test for Lp-PLA2, visit www.plactest.com.

Sources

  1. DiaDexus Raises $40M Series E For Expansion (scalevp.com) [edit]
  2. diaDexus lands $9.2M for cardiovascular diagnostics (deals.stage.venturebeat.com) [edit]
  3. SEC (sec.gov) [edit]
Edit This Page
Last Edited 1/1/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy